ONCBeOne Medicines AG
Price
+5.9%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, growth steady, the market undecided.
We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. In 2025, we generated total global revenue of approximately $5.3 billion, increasing revenue by approximately 40.2% from the prior year, while achieving net income of $286.9 million, net cash provided by operating activities of $1.1 billion and positive free cash flow of $941.7 million.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Its largest product in Jun 2026 was BRUKINSA at $1.25B, 72% of the disclosed total, well ahead of TEVIMBRA at 13%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 26, 2026Key Differences between U.S. GAAP and PRC GAAP.Earnings release · press release
- Aug 5, 2026BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates.Earnings release · press release
- Jun 26, 2026As previously disclosed in the Quarterly Report on Form 10-Q filed by BeOne Medicines Ltd. (the “Company”) with the Securities and Exchange Commission on May 6, 2026, the Company is subject to ongoing tax audits that may result in liabilities which could be materially different from current estimates due to the …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $1.73BThe company’s own SEC segment disclosure.
- BRUKINSA$1.25B72%
- TEVIMBRA$228.5M13%
- XGEVA$104.5M6%
- Other$37.8M2%
- BLINCYTO$36.5M2%
- Other$25.3M1%
- Other (5)$50.1M3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry